Projection For 2021With the company recently getting HC approval for a very cost effective drug, deemed best in class, and the stream of others in the 2021 pipeline, don't be shocked if they become a target from one of their many drug partners. This is a solid winning growth story with the company now moving to positive EBITDA and no looking back.